Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Drug or compound screening involving gene expression

Subclass of:

435 - Chemistry: molecular biology and microbiology

435004000 - MEASURING OR TESTING PROCESS INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITION OR TEST STRIP THEREFORE; PROCESSES OF FORMING SUCH COMPOSITION OR TEST STRIP

435600100 - Involving nucleic acid

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
435600130 Drug or compound screening involving gene expression 89
20130045484METHODS AND KITS FOR DETERMINING THE TOXICITY OF AN AGENT - The invention relates to methods and kits for determining the toxicity of an agent on a population of eukaryotic cells, particularly human cells. The cells may comprise a nucleic acid construct comprising a DNA damage induced response element operably linked to a sequence encoding a reporter gene. The multiplex methods and kits provide means for distinguishing between genotoxic and cytotoxic agents.02-21-2013
20130045483YEAST CELLS EXPRESSING AMYLOID BETA AND USES THEREFOR - Disclosed are yeast cells expressing a polypeptide comprising a signal sequence and a human amyloid beta protein. Also disclosed are methods of screening yeast cells to identify compounds that prevent or suppress amyloid beta-induced toxicity and genetic suppressors or enhancers of amyloid beta-induced toxicity. Compounds identified by such screens can be used to treat or prevent neurodegenerative disorders such as Alzheimer's disease.02-21-2013
20120183972DNA CAPABLE OF INDUCING OSTEOBLAST-SPECIFIC EXPRESSION, AND NUCLEOTIDE SEQUENCE FOR SAME - The invention provides nucleotide sequences that function as enhancers and induce osteoblast-specific expression, expression vectors comprising such an enhancer, a promoter, and a gene containing a coding region, as well as screening methods utilizing such expression vectors.07-19-2012
20110195420ESTROGEN AND ANTI-ESTROGEN MARKER GENES - The invention relates to a method for screening compounds with estrogenic or anti-estrogenic activity by providing a cellular system of a sample thereof being capable of expressing at least a single gene of Table 1, incubating at least a portion of the system with compounds to be screened, and comparing an expression of the single gene of Table 1 in the system with the gene expression in a control cellular system. Another object of the invention concerns a method for monitoring physiological and/or pathological conditions, which are caused, mediated and/or propagated by estrogen receptor signaling, by administering an effective amount of at least a single compound to a mammal in need of such treatment and determining an expression of the single gene of Table 1 in a biological sample withdrawn from the mammal. The invention also relates to the use of the genes of Table 1 as well as substances specifically interacting with gene products encoded by the genes of Table 1.08-11-2011
20110195419THERAPEUTIC USE OF FARNESYLTRANSFERASE INHIBITORS AND METHODS OF MONITORING THE EFFICACY THEREOF - The therapeutic use of farnesyltransferase inhibitors (e.g., tipifarnib) for the treatment of sepsis is described. Methods useful to monitor the effectiveness of such treatment are also described.08-11-2011
20130084578BREAST CANCER RELATED GENE ZNFN3A1 - Objective methods for detecting and diagnosing breast cancer (BRC) are described herein. Also described are methods of treating and preventing breast cancer and breast cancer metastasis as well as methods of assessing the prognosis of a breast cancer subject and the efficacy of a breast cancer therapy. In one embodiment, the diagnostic method involves determining the expression level of ZNFN3A1, a gene whose expression is markedly elevated in breast cancers, that therefore can be used to discriminate between BRC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of BRC, methods of treating BRC and method for vaccinating a subject against BRC.04-04-2013
20110311986CELL LINES COMPRISING SOUR-TASTE RECEPTORS - The present invention relates to sour taste receptors and compositions and methods thereof. In particular, the present invention provides assays and methods of screening for ligands specific for sour taste receptors. Additionally, the present invention provides methods for screening for accessory proteins and mutations, polymorphisms and other potential sour taste receptor protein mutations that are associated with disease states, and therapeutic agents, ligands, and modulators of such proteins. The present invention also provides compositions and methods for modulating sour taste receptors in vitro and in vivo.12-22-2011
20130071853METHODS FOR IDENTIFYING COMPOSITIONS THAT ALTER WILDTYPE EXPRESSION OF GENES AND PROTEINS IN A PLANT CELL - A method for identifying compounds that selectively alter wildtype gene expression of a plant cell includes comparing a first expression profile from a plant cell or tissue contacted with a first test compound, an additional expression profile from the same plant cell or tissue contacted with an additional test compound, and a combined compound expression profile from the same plant cell or tissue contacted with the first test compound and the additional test compound, wherein each plant cell or tissue was contacted for a time sufficient to produce an alteration in the expression of at least one gene or gene product in the plant's cells or tissues; and wherein each expression profile comprises the expression level or pattern of at least one gene or gene product of the plant cell or tissue; and identifying a significant, unexpected alteration in the level or pattern of expression between the genes or gene products of the combined compound profile and those of the additive alterations of the first profile and the additional profile.03-21-2013
20130059312Methods Of Using Chimeric Receptors to Identify Autoimmune Disease - The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays.03-07-2013
20130059311METHOD FOR THE IDENTIFICATION OF MEMORY MODULATING COMPOUNDS BY ASSESSING KIBRA EXPRESSION - Provided are cell based methods to identify memory modulating compounds based on the assessment of KIBRA expression. These methods are also suitable to uncover memory related pathways. The methods comprise the contacting of test compounds with cultured cells and the subsequent assessment of modulation of the KIBRA expression within the cells.03-07-2013
20130065243METHOD FOR PRODUCING INDUCED PLURIPOTENT STEM CELLS - A major object of the present invention is to provide a method for producing induced pluripotent stem cells with low tumorigenesis potential and high induction efficiency.03-14-2013
20130164758Enzyme Regulating Ether Lipid Signaling Pathways - A multidimensional profiling strategy that combines activity-based proteomics and metabolomics was used to determine that an active protein, which is a previously uncharacterized enzyme highly elevated in aggressive cancer cells, serves as a central node in an ether lipid signaling network that bridges platelet-activating factor and the lysophospholipids. Biochemical studies confirmed that the active protein regulates this pathway by hydrolyzing the metabolic intermediate 2-acetyl monoalkylglycerol. Inactivation of the active protein disrupted ether lipid metabolism in cancer cells and impaired cell migration and tumor growth in vivo.06-27-2013
20130022986METHOD FOR MANUFACTURING PANCREATIC-HORMONE-PRODUCING CELLS - The present invention provides a method of more efficiently producing pancreas cells, particularly pancreatic hormone-producing cells, a method of stably producing pancreas cells in a large amount by more efficiently inducing differentiation of stem cells into pancreas cells, a medicament containing a pancreas cells and a screening method using the cells.01-24-2013
20110287439CLASTOGENICITY TESTING - The present invention relates to improved methods for detecting agents that cause or potentiate DNA damage and to genetically transformed cells that may be usefully employed in such methods.11-24-2011
20110287438Sensor chip for screening topoisomerase inhibitor and screening method thereof - The present invention discloses a sensor chip for screening a topoisomerase inhibitor and a screening method thereof. The sensor chip comprises topoisomerase I and a biochip. The topoisomerase I is immobilized on the biochip, and the topoisomerase I has DNA catalytic activity. This provides a rapid screening method for topoisomerase I inhibitors.11-24-2011
20110287437ASSAYS TO PREDICT CARDIOTOXICITY - The likelihood that a compound will exhibit cardiotoxicity in vivo can be predicted using a model of in vitro assays performed on primary human cardiomyocytes.11-24-2011
20120295272PROINFLAMMATORY NUCLEIC ACIDS - The present invention provides compositions and methods for identifying and utilizing proinflammatory nucleic acids. In particular, this invention relates to compounds, particularly oligonucleotides, which exert their effect through triggering receptors expressed by myeloid cells (TREMs), specifically TREM 2.11-22-2012
20110171659Multipotent Adult Stem Cells, Sources Thereof, Methods of Obtaining and Maintaining Same, Methods of Differentiation Thereof, Methods of Use Thereof and Cells Derived Thereof - The present invention relates generally to mammalian multipotent adult stem cells (MASC), and more specifically to methods for obtaining, maintaining and differentiating MASC to cells of multiple tissue types. Uses of MASC in the therapeutic treatment of disease are also provided.07-14-2011
20110207144IN VITRO SCREENING ASSAYS - Disclosed herein are methods for identifying inhibitors of the catalytic activity of LOXL2 using in vitro assays. In certain embodiments, inhibitors identified by these in vitro assays are effective in inhibiting tumor desmoplasia and fibrosis.08-25-2011
20120070843DBC1, A NOVEL NATIVE INHIBITOR OF THE ANTI-AGING PROTEIN SIRT1 - A novel complex is identified between the NAD-dependent deacetylase, SIRT1 and its novel inhibitor, DBC1. Provided herein are methods to indentify a compound that inhibits the complexation between SIRT1 and DBC1. Exemplary methods comprise contacting either the complexation between DBC1 and SIRT1 with an agent being tested for its ability to inhibit the complexation between SIRT1 and DBC1. Also, provided are methods to identify a compound that increases the complexation between SIRT1 and DBC1. Exemplary methods comprise contacting either the complexation between DBC1 and SIRT1 with an agent being tested for its ability to increase the complexation between SIRT1 and DBC1. Further, methods are provided to increase or decrease SIRT1 activity by contacting the complexation between SIRT1 and DBC1 with a peptide that either decreases or increases the complexation between SIRT1 and DBC1. Further, methods are provided for the treatment of patients suffering from diseases including metabolic diseases including obesity and diabetes, and neurodegenerative disorders including Alzheimer's disease and Huntington's disease using compounds that inhibit the complexation between SIRT1 and DBC1.03-22-2012
20120171690Transgenic Animals for Analyzing CYP3A4 Cytochrome P450 Gene Regulation - The invention relates to the generation of non-human transgenic animals comprising a reporter construct for producing a detectable amount of a reporter molecule operably linked to a transcriptional regulatory nucleic acid molecule from the human CYP3A4 gene located between the initiation of transcription site of the gene and a position located 13,000 nucleotides upstream from the site. The invention also relates to the use of these animals for determining the effect of a compound, particularly, but not exclusively, a xenobiotic or steroid, on the regulation of expression of the CYP3A4 gene in a human.07-05-2012
20110143359Method for Identifying Drug-Sensitizing Antisense DNA Fragments and Use Thereof - The invention provides a method for generating and selecting drug-sensitizing antisense DNA fragments. In one embodiment, the method includes identifying a gene of interest using knowledge of bacterial physiology, biochemistry, genetics, genomics, and other means. The method includes PCR amplification of a gene of interest using genomic DNA as a template; fragmentation of the DNA by sonication or other means; selecting DNA fragments no longer than 400 base pairs; ligating the DNA fragments into a suitable expression plasmid with a selectable marker; transforming the plasmids containing the DNA fragments into the organism from which the gene of interest originated; and selecting clones from transformed cells that show a phenotypic difference of the clone grown in the presence of the inducer relative to the phenotype in the absence of inducer.06-16-2011
20120034616Method for Modulating Epithelial Stem Cell Lineage - The present invention relates to methods of modulating epithelial stem cell lineage by regulating the expression of Lef1 or a BMP inhibitor and/or the stability of β-catenin or the expression of a Wnt; regulating the expression or activity of GATA-3; or regulating BMPR1A activity either at the level of receptor expression or at the level of pathway activation. Methods of regulating E-cadherin, GATA-3, BMPR1A and HK1-hair keratin and methods of identifying agents which modulate the epithelial stem cell lineage are further provided. Such agents are useful for inhibiting or stimulating inner root sheath development or hair follicle formation.02-09-2012
20110189686SCREENING FOR MODULATORS OF CYP2B15 AND/OR GPD1 FOR THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the CYP2B15 and/or glycerol-3-phosphate dehydrogenase 1 (GPD1) proteins.08-04-2011
20110244471SCREENING METHOD AND VECTOR, VECTOR LIBRARY, AND ASSAY KIT USED THEREFOR - According to one embodiment, a method of screening an enhancer and/or a promoter, includes culturing a host cell into which an amplifiable vector is introduced, extracting the vector from the host cell and obtaining the DNA fragment from the extracted vector, wherein the vector includes a DNA fragment to be determined, a gene that is functionally linked downstream of the DNA fragment and encodes a protein to initiate self-replication, and a gene that encodes a replication origin sequence.10-06-2011
20110212455METHOD OF SCREENING MATERIAL FOR IMPROVING SKIN FUNCTIONS - A method of screening a material for improving skin functions includes: (a) treating a skin cell with a candidate material; (b) detecting a change in a relative expression level of membrane-associated protein 17 (MAP17) gene; and (c) selecting a candidate material inducing the change in the expression level of the gene as a material for improving skin functions.09-01-2011
20110244472Cancer stem cell immortalization - The present invention relates to the preparation and use of immortalized cancer stem cells. The immortalized cancer stem cells of the invention may be used in assays to identify anti-cancer compounds as well as molecules critical to carcinogenesis. Further, cancer stem cells may be harvested from a patient and used, according to the invention, to select agents more likely to be effective in treating the cancer of that particular patient.10-06-2011
20110151470BIOMARKERS FOR ASSESSING RESPONSE TO C-MET TREATMENT - Biomarkers that correlate to treatment with drugs that inhibit c-met are disclosed. These biomarkers have been shown to have utility in assessing response to the compounds. The expression level of the biomarkers is reduced upon treatment with c-met inhibitor compounds, thus indicating that these biomarkers are involved in c-met activity.06-23-2011
20110250607YEAST-BASED METHODS OF IDENTIFYING NUCLEIC ACIDS AND COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES - The disclosure encompasses methods for the screening of small molecules or nucleic acids that may reverse the inhibition of growth of the unicellular yeast 10-13-2011
20110250606METHOD FOR THE IDENTIFICATION OF CARCINOGENIC COMPOUNDS - The present invention relates to methods for the identification of genotoxic carcinogenic compounds. In particular, a method is disclosed for the identification of genotoxic carcinogenic compounds wherein a eukaryotic cell is exposed to a potentially genotoxic compound in a culture medium where after samples are taken from the cell and/or the culture medium at at least one predetermined time point which samples are then analysed for increased or decreased expression levels of at least three DNA repair genes as compared to a control cell that is not exposed to the carcinogenic compound.10-13-2011
20110151469INTERFERON EPSILON (IFNE1) AS A MARKER FOR TARGETED CANCER THERAPY - The present invention relates to a method employing Interferon Epsilon (IFNE1) as a therapeutic response, prognostic, or pharmacodynamic marker for cancer chemotherapeutic treatment involving the use of cyclin dependent kinase (CDK) inhibitors. The inventors have identified IFNE1 as a biomarker transcript that is upregulated when cancer cells are treated with CDK inhibitors. In an embodiment, the method of the invention includes measuring a level of IFNE1 mRNA or IFNE1 protein in a subject's tumor, blood or other tissue. An increase in the level of IFNE1 compared to control level can indicate that the CDK inhibitor has produced a therapeutic response or can determine whether a tumor is sensitive to a CDK inhibitor.06-23-2011
20110151468METHODS AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS - Disclosed herein are methods and compositions useful for identifying therapies likely to confer optimal clinical benefit for patients with cancer.06-23-2011
20120202215MITOCHONDRIAL FUNCTION OF PROHIBITIN 2 (PHB2) - The present invention relates to a PHB2 gene regulator and a therapeutic drug for mitochondrial-function-related disease containing the same, for example.08-09-2012
20110151471RIBOSWITCHES, METHODS FOR THEIR USE, AND COMPOSITIONS FOR USE WITH RIBOSWITCHES - It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural “riboswitches” (created by using various nucleic acid engineering strategies) can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies. In addition, the architecture of riboswitches allows actual pieces of the natural switches to be used to construct new non-immunogenic genetic control elements, for example the aptamer (molecular recognition) domain can be swapped with other non-natural aptamers (or otherwise modified) such that the new recognition domain causes genetic modulation with user-defined effector compounds. The changed switches become part of a therapy regimen—turning on, or off, or regulating protein synthesis. Newly constructed genetic regulation networks can be applied in such areas as living biosensors, metabolic engineering of organisms, and in advanced forms of gene therapy treatments.06-23-2011
20110256545mRNA expression-based prognostic gene signature for non-small cell lung cancer - A non-small cell lung cancer postoperative survival prognosticator comprising a detection mechanism consisting of 15-gene, 12-gene, and 16-gene signature and methods of use. Also provided are the identification of various subsets from the 25 prognostic signature genes with potential of operative survival prognosticator for non-small cell lung cancer patients in all tumor stage and early stage and potential for chemoresponse with a method of use.10-20-2011
20120064537USE OF PERFUSION DECELLULARIZED ORGANS FOR MATCHED RECELLULARIZATION - The invention provides a method for preparing a perfusion based 3D cell culture system, a recellularized matrix culture system, and methods of using the culture system.03-15-2012
20110256544MOLECULES INTERACTING WITH CASL (MICAL) POLYNUCLEOTIDES, POLYPEPTIDES, AND METHODS OF USING THE SAME - The present invention provides MICAL and MICAL-Like polypeptides and polynucleotides. Also provided are methods that for identifying agents that affect axon growth and placement. Furthermore, provided herein are methods for affecting axon growth and placement.10-20-2011
20110136128REPORTER ASSAY SCREENS FOR PROTEIN TARGETS IN SACCHAROMYCES CEREVISIAE - The present invention comprises responsive promoters along with screening methods which make use of the promoters in order to identify anti-fungal substances.06-09-2011
20130295578METHODS FOR SCREENING FOR DRUG RESISTANCE IN CANCER TREATMENT - The present invention includes methods for screening for drug resistance in cancer tissue ex vivo which comprises a novel 3-dimensional cell culture system that mimics the tumor microenvironment.11-07-2013
20120040365NEW COMPETENCE STIMULATING PEPTIDE - The present invention concerns a new competence stimulating peptide identified in Firmicutes, in particular 02-16-2012
20130295579METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELLS AND MEDIUM USED FOR PREPARING INDUCED PLURIPOTENT STEM CELLS - A method for preparing induced pluripotent stem (iPS) cells, which comprises steps as follows: step 1, introducing one or more stem cell pluripotency factors into somatic cells; step 2, culturing the somatic cells, into which the stem cell pluripotency factor has been introduced in the Step 1, by using medium supplemented with lithium salt; and step 3, identifying and characterizing the induced pluripotent stem cells. Furthermore, there provided a medium for preparing induced pluripotent stem cells, which comprising lithium salt. The medium supplemented with lithium salt is used for efficiently inducing pluripotent stem cells. Lithium salt is able to increase the production efficiency of mouse iPS cells by 5-60 times. The present method for inducing iPS cells is in favor of improving the safety of iPS technique and application of iPS cells in regenerative medicine.11-07-2013
20110165581METHODS FOR SCREENING FOR COMPOUNDS FOR TREATING CANCER - The methods described herein provide nucleic acid constructs and screening methods for identifying and validating compounds for use in the treatment of cancer, wherein the compounds down-regulate the post-transcriptional expression of Bmi-1.07-07-2011
20130224754METHOD FOR THE SELECTION OF COMPOUNDS USEFUL FOR THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES - The present invention concerns a method for the identification of specific compounds which modulate brain-derived neurotrophic factor, which can be used as drugs for the treatment of neurological and neuropsychiatric diseases and which are suitable for the treatment of deleterious effects caused to the nervous system by abuse of illegal or legal drugs.08-29-2013
20130011850STEROIDOGENESIS MODIFIED CELLS AND METHODS FOR SCREENING FOR ENDOCRINE DISRUPTING CHEMICALS - An isolated steroidogenesis modified cell comprising one or more steroid biosynthesis knock down nucleic acid operatively linked to a promoter, wherein the steroid biosynthesis knock down nucleic acid reduces the expression of a gene selected from the group CYP21A2, CYP11A1, CYP17A1, CYP19A1, 3-βHSD1, 3-βHSD2, 17-βHSD1, StAR, HMGR, CYP11B2, CYP11B1, 5α-Reductase 2, SULT1E1, CYP3A4 and UTG1A1, wherein the cell comprises reduced expression of one or more of said genes. The cells are useful for identifying endocrine disruptors. Accordingly, the disclosure includes in a further aspect a screening assay for identifying an endocrine disruptor comprising: 01-10-2013
20120122111RNA SEQUENCE-SPECIFIC MEDIATORS OF RNA INTERFERENCE - The present invention relates to a 05-17-2012
20110183347Compositions and methods for therapeutic delivery with microorganisms - Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that include modified microorganisms including at least one genetic element encoding at least one therapeutic agent or environmental treatment agent.07-28-2011
20120129184SYSTEMIC CARNITINE DEFICIENCY GENE AND USES THEREOF - The gene responsible for systemic carnitine deficiency was found to be the OCTN2 gene involved in the transportation of organic cations. This invention enables tests for this disease by detecting whether or not the OCTN2 gene has a mutation. Furthermore, systemic carnitine deficiency can be treated using the normal OCTN2 gene and its protein.05-24-2012
20120164656Methods To Identify Compounds Useful For The Treatment Of Proliferative And Differentiative Disorders - The present invention relates to the discovery, identification and characterization of nucleotide sequences that encode novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleotides encoding novel substrate-targeting subunits of ubiquitin ligases, and transgenic mice, knock-out mice, host-cell expression systems and proteins encoded by the nucleotides of the novel substrate-targeting subunits. The present invention relates to screening assays that use novel and known substrate-targeting subunits of ubiquitin ligases to identify potential therapeutic agents such as small molecules, compounds or derivatives and analogues of the novel and known ubiquitin ligases which modulate activity of the novel and known ubiquitin ligases for the treatment of proliferative and differentiative disorders, such as cancer, major opportunistic infections, immune disorders, certain cardiovascular diseases, and inflammatory disorders. The invention further encompasses therapeutic protocols and pharmaceutical compositions designed to target ubiquitin ligases and their substrates for the treatment of proliferative and differentiative disorders.06-28-2012
20130260385IDENTIFICATION AND ENRICHMENT OF CELL SUBPOPULATIONS - Markers useful for the identification, characterization and, optionally, the enrichment or isolation of tumorigenic cells or cell subpopulations are disclosed.10-03-2013
20120315643Alternative Splicing Constructs and Methods of Use - Provided are alternative splicing constructs and methods for their use. In particular, CD44 based alternative splicing constructs are provided that include CD44 exon 5. These alternative splicing constructs are useful in high-throughput assays for testing the effects of compounds on splicing and for achieving targeted cell death.12-13-2012
20120225434SCREENING METHOD FOR SELECTED AMINO LIPID-CONTAINING COMPOSITIONS - The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-Dilinoley 1-4-dimethylaminomethyl-[1,3]-dioxolane by screening for an effect of the agent on the liver of a model subject.09-06-2012
20120082996IL-21 VARIANTS - IL-21 variants nucleic acid sequences are provided that encode a peptide having deletions and zero to ten conservative amino acid substitutions in the region of amino acid residues 65-96 of SEQ ID. NO:2.04-05-2012
20120264134METHODS AND APPARATUS FOR THE MANIPULATION OF PARTICLE SUSPENSIONS AND TESTING THEREOF - Apparatus and methods are provided for analysis of individual particles in a microfluidic device. The methods involve the immobilization of an array of particles in suspension and the application of experimental compounds. Such methods can also include electrophysiology studies including patch clamp recording, electroporation, or both in the same microfluidic device. The apparatus provided includes a microfluidic device coupled to a multi-well structure and an interface for controlling the flow of media within the microchannel device.10-18-2012
20120322077CELL, METHOD, AND ASSAY KIT FOR MEASURING LEVEL OF ARYL HYDROCARBON RECEPTOR TRANSCRIPTIONAL ACTIVATION - According to one embodiment, a cell for measuring a level of Ah receptor transcriptional activation is provided. The cell is derived from a neural cell. The cell contains a chromosome into which a reporter construct and an Ah receptor gene are introduced. The reporter construct has a sequence represented by SEQ ID NO: 1 and a reporter gene operably linked to the downstream of the nucleotide sequence. The sequence represented by SEQ ID NO: 1 has a recognizing sequence of an Ah receptor and a nucleotide sequence which is operably linked to the downstream of the recognizing sequence and required to initiate transcription.12-20-2012
20120276545METHOD FOR USING DIVISION ARRESTED CELLS IN SCREENING ASSAYS - Division arrested cells are used in screening assays to determine the effect of a substance of interest on the cells. The division arrested cells can be used in drug screening assays, signal transduction assays, and are especially useful in large scale, high throughput assays.11-01-2012
20130230862METHODS TO IDENTIFY COMPOUNDS USEFUL FOR TUMOR SENSITIZATION TO DNA DAMAGE - Cdc25A is herein identified as a substrate for β-TrCP1- or β-TrCP2-mediated ubiquitination and subsequent degradation via the ubiquitin-proteasome pathway. In particular, it has been found that interfering with β-TrCP expression or function, or increasing β-TrCP degradation, leads to accumulation of Cdc25A in a cell. Since degradation of Cdc25A is a key feature of the response to DNA damage, leading to a stall in the cell cycle during which the cell can repair the damage, Cdc25A accumulation can abolish this response, thereby sensitizing the cell to DNA damage. Described herein are assays for identifying β-TrCP inhibitors, and method of using such inhibitors for modulating Cdc25A degradation, sensitization of tumor cells, and as adjuvants in cancer therapy based on DNA damaging agents.09-05-2013
20130230861METHOD FOR DETECTION OF IDIOPATHIC INTERSTITIAL PNEUMONIA - The present invention provides a method for detecting idiopathic interstitial pneumonia, which comprises measuring the expression level of a periostin gene or the amount of a periostin protein in a biological sample. Thereby, a method for detecting idiopathic interstitial pneumonia using a marker is provided.09-05-2013
20110244470ISOLATED TRANSGENIC MAMMALIAN NEURAL CELL FOR DETECTION OF A SAMPLE CONTAINING A CHEMICAL SUBSTANCE DAMAGE TO NEUROLOGICAL SYSTEM OR SELECTION OF DRUGS FOR TREATING NEURODEGENERATIVE DISORDERS - The invention is to provide an isolated transgenic mammalian neural cell, which comprises at least one heterologous vector expressing AhR/ARNT. Also provided is methods the detection of a sample containing a chemical substance damage to the nervous system and the selection of drugs for treating neurodegenerative disorders.10-06-2011
20120329066FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS - Although it can be farnesylated, mutant lamin A expressed in Hutchinson Gilford Progeria Syndrome cannot be defarnesylated; the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (“progerin”) that alters normal lamin A function as a dominant negative, and assumes its own aberrant function through its association with the nuclear membrane. Retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) will inhibit formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with FTIs.12-27-2012
20120329067Methods of Generating Zinc Finger Nucleases Having Altered Activity - Provided herein are zinc linger nucleases having altered, arid in particular, improved catalytic activity and methods of generating such nucleases. Accordingly, there are provided methods for identifying improved catalytic activity of a ZFN by expressing a mutated zinc finger nuclease in a cell containing a reporter construct with a toxic gene, and a zinc finger nuclease cleavage site that is recognized by the ZFN. Survival of the cell is positively correlated with catalytic activity of the ZFN; thus, libraries of mutated ZFKs may be selected for altered catalytic activity based on relative survival rates, Methods of using identified ZFNs are also provided.12-27-2012
20110159507METHOD FOR DETECTING THE DRUG EFFECTS OF DNA METHYLATION-INHIBITORS - Disclosed is a method for detecting the drug effects of DNA methylation inhibitors that detects the drug sensitivity of gene-expressing cells to DNA methylation inhibitors based on gene expression of a transcription factor (PU. 1) and/or gene expression of metallothionein (MT) that participates in differentiation to neutrophil and monocyte lines or based on DNA methylation in the metallothionein (MT) gene promotor region. Hematopoietic tumors can be treated effectively and specifically after predicting the effects of DNA methylation inhibitors on the hematopoietic tumor cells of myelodysplastic syndrome, acute myelocytic leukemia (AML), and other hematopoietic organ diseases, so therapeutic results are improved.06-30-2011
20110159506METHODS FOR ASSESSING RNA PATTERNS - Methods and compositions for the characterizing of cancers by assessing RNA levels, such as determining an RNA pattern, are provided herein. The diagnosis, prognosis, monitoring and treatment or a cancer can be determined by detecting one or more RNAs, such as microRNAs.06-30-2011
20130171655NOVEL BIOLOGICAL DETECTION METHOD FOR DIOXINS IN SERUM, AND A DIAGNOSTIC USE THEREFOR IN METABOLIC SYNDROME AND RELATED CONDITIONS - The present invention relates to a novel biological detection method for dioxins in serum and a diagnostic use thereof in metabolic syndrome and related conditions. More particularly, according to the present invention, a significant correlation between dioxin content in serum and physical variables has been confirmed by measuring luciferase activity through the use of serum as a whole and cells transformed with a recombinant vector comprising a gene construct in which a dioxin responsive element, a promoter and a reporter gene are operably linked. And there is an improvement in this method of the present invention over the conventional methods which require a preprocessing step in order to purify dioxins from serum, by which plural samples can be analyzed easily and accurately even with a very small amount of each because of the use of serum as a whole. Therefore, the detection system of the present invention which involves total serum processing in a genetically transformed cell line comprising a recombinant reporter gene whose expression is modified by dioxin compounds can be effectively used for the biological detection of dioxins in serum. This method can also be used to research the correlation between specific POPs and patient's disease factors by accurate detection of POPs such as dioxins in the serum, and further this method can be effectively used to predict the occurrence of disease and to determine treatability.07-04-2013
20130177919PROTEIN PRODUCTION - The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport.07-11-2013
20120252028TARGET GENES FOR CANCER THERAPY - The invention provides new gene targets for cancer chemotherapy, their use in assays for identifying new small molecule cancer chemotherapeutic agents, methods for inhibiting cancer cell growth comprising contacting a cell with a gene expression blocking agent that inhibits the expression of such genes and methods for therapeutic treatment of cancer in a mammal, comprising administering to the mammal such a gene expression blocking agent. A preferred gene target is coatomer protein zeta-1 subunit (COPZ1).10-04-2012
20110269141TARGET PROTEIN AND TARGET GENE FOR DRUG DISCOVERY, AND SCREENING METHOD - The problems of the present invention are to provide target proteins and target genes for bioactive substances such as drugs, and means that enable the development of novel bioactive substances using the same. The present invention provides target proteins and target genes for bioactive substances; screening methods for substances capable of regulating bioactivities; bioactivity regulators; a bioactive substance derivative production method; a complex comprising a bioactive substance and a target protein, and a method of producing the complex; and kits comprising a bioactive substance or a salt thereof; determination methods for the onset or risk of onset of a specified disease or condition, determination methods for susceptibility to a bioactive substance, and determination kits used for the determination methods, and the like.11-03-2011
20130171654DNA INTERCALATOR DETECTION - A DNA intercalator detection system can include a filtration unit a control sample conditioner operably coupled with the filtration unit and an analytic unit operably coupled with the filtration unit and control sample conditioner and having an electronic chemical array (ECA) reaction component. A data processing unit is operably coupled with the analytic unit and configured to compare and determine a difference between electronic data of a test sample and a conditioned control sample from the ECA reaction component. The difference provides an indication of whether or not a DNA intercalator is present in the test sample.07-04-2013
20130236905ASSAY FOR IDENTIFYING ANTIGENS THAT ACTIVATE B CELL RECEPTORS COMPRISING NEUTRALIZING ANTIBODIES - The invention described herein provides a method for screening pathogenic viral envelope proteins and protein complexes to identify protein constructs with enhanced effectiveness as vaccine immunogens. The method is carried out by (i) expressing of a membrane-bound isotype of an antibody that has the same binding activity and specificity of an antibody that is known, or identified, to bind and neutralize the targeted virus, and that has the capacity to activate signaling pathways down-stream of B cell receptor ligand binding and activation—a modified neutralizing antibody-based B cell receptor; (ii) exposing the cell to antigen; and (iii) assay for signaling downstream of B cell receptor activation. The present invention also provides the antigens identified using the as say described herein, and neutralizing antibodies derived by immunization with the antigens identified using the assay described herein.09-12-2013
20130102007COMPOSITIONS AND METHODS FOR CHARACTERIZING AND REGULATING OLFACTORY SENSATION - The present invention relates to the characterization of odorant receptors. In particular, the present invention relates to the OR7D4 proteins and nucleic acids encoding OR7D4 proteins and cell systems for screening for modulators of OR7D4 receptors. The present invention further provides assays for the detection of OR7D4 polymorphisms and mutations associated with altered olfactory sensation states, as well as methods of screening for therapeutic agents, ligands, and modulators of OR7D4 receptors.04-25-2013
20130130269SCREENING TOOL FOR ANTI-INFLAMMATORY DRUG DISCOVERY COMPRISING THE FPR2/ALX GENE PROMOTER - A screening tool for anti-inflammatory drug discovery and for the detection of the risk or presence of inflammatory conditions, comprising the sequence of the FPR2/ALX gene promoter, is disclosed.05-23-2013
20110229904RECOMBINANT CONSTRUCT FOR DETECTION OF HALOGENATED AROMATIC HYDROCARBONS - The present invention describes a recombinant construct for detection of halogenated aromatic hydrocarbon compounds. A method for detecting halogenated aromatic hydrocarbon compounds using the recombinant construct is also described.09-22-2011
20110236902TESTING A PATIENT POPULATION HAVING A CARDIOVASCULAR CONDITION FOR DRUG EFFICACY - Lumenectomy material is tested to determine the efficacy of a test drug in a patient population having a cardiovascular condition. The material is removed from at least a first and a second patient and tested for one or more markers of a cardiovascular condition. The first patient is administered the test drug, and the second patient is administered a placebo. At a later date, more lumenectomy material is removed and tested for the same marker or markers. The presence, absence or amount of the markers is compared in the first patient receiving the drug and the second patient receiving the placebo to determine whether the drug is effective in the patient population. The drugs tested include drugs believed to be effective in treating a cardiovascular condition. The markers used can include any marker that can indicate the effectiveness of the drug being tested.09-29-2011
20120276546Periodontal Disease Marker - A marker for determining the onset of periodontal disease and a marker far determining the progression stage of periodontal disease, each containing autoinducer-2.11-01-2012
20110275088USE OF EEF1A AS BIOMARKER AND A METHOD OF SCREENING METAP2 INHIBITORS - The invention relates to a method for screening compounds, which inhibit MetAP2 activity, by providing a cellular system or a sample thereof being capable of expressing MetAP2 and/or EEF1A, incubating at least a portion of the system with compounds to be screened, and detecting MetAP2 inhibition by determining EEF1A with N-terminal methionine residue (MetEEF1A). Another object of the invention concerns a method for monitoring physiological and/or pathological conditions, which are caused, mediated and/or propagated by MetAP2 activity, by administering an effective amount of at least a single compound to a mammal in need of such treatment and determining MetEEF1A in a biological sample withdrawn from the mammal. The invention also relates to the use of EEF1A as biomarker.11-10-2011
20130157280PLANT FARNESYLTRANSFERASES - This invention relates to an isolated nucleic acid fragment encoding a farnesyltransferase subunit. The invention also relates to the construction of a chimeric gene encoding all or a portion of the farnesyltransferase subunit, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the farnesyltransferase subunit in a transformed host cell.06-20-2013
20110311985RNAI BASED SELECTION SYSTEM - The present invention provides a novel RNAi based selection system for selecting host cells that have incorporated an expression vector.12-22-2011
20110311984COMPOSITION FOR DIAGNOSING PARKINSON'S DISEASE CONTAINING ADIPOSE TISSUE-DERIVED MESENCHYMAL STROMAL CELL - The present invention relates to a composition for diagnosing a Parkinson's disease comprising mesenchymal stromal cells derived from adipose tissue, a method of providing information for diagnosing Parkinson's disease and/or the extent of the disease progression, a biomarker for diagnosing a Parkinson's disease, and a method of screening a drug candidate treating Parkinson's disease where the drug candidate is a target of the biomarker.12-22-2011
20130244244PREDICTING ALLERGIC REACTIONS - This present invention provides a method of predicting immunogenicity and hypersensitivity or allergic reactions to chemical compounds, therapeutics, cosmetics and other chemical compositions. The method uses an in vitroassay employing autologous bloodderived cells and an autologous cultured skin biopsy and is of particular utility in the identification and prediction of skin sensitizers that cause allergic contact dermatitis.09-19-2013
20130244243METHOD FOR PRODUCING EXPRESSION PRODUCT OF EXOGENOUS GENE IN YEAST, REGULATOR OF EXPRESSION IN YEAST, AND USE THEREOF - Provided is a method for producing an expression product of an exogenous gene in a yeast with superior output regulation of gene expression. This is a method for producing an expression product of an exogenous gene in a yeast, including using one or two or more kinds of yeast gene terminator regions selected based on expression intensity data related to the expression intensity of yeast gene terminator regions to cause expression of a gene in a yeast.09-19-2013
20130252253PLANT DIACYLGLYCEROL ACYLTRANSFERASES - This invention relates to an isolated nucleic acid fragment encoding a diacylglycerol acyltransferase. The invention also relates to the construction of a chimeric gene encoding all or a portion of the diacylglycerol acyltransferase, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the diacylglycerol acyltransferase in a transformed host cell.09-26-2013
20130252252CLONED TRANSMEMBRANE RECEPTOR FOR 24-HYDROXYLATED VITAMIN D COMPOUNDS AND USES THEREOF - The instant invention relates to the use of 24-hydroxylated vitamin D compounds as therapeutics in mammalian bone fracture repair. In addition, the instant invention relates to novel 24-hydroxylated vitamin D compound receptors which can be employed in the development of compounds capable of facilitating fracture repair in animals. The instant invention also relates to nucleic acids encoding such receptors as well as vectors, host cells, transgenic animals comprising such nucleic acids and screening assays employing such receptors.09-26-2013
20120028263METHOD FOR SCREENING A SALTY TASTE MODULATING SUBSTANCE - By contacting a test substance with a cell that expresses a Kv3.2 protein, and comparing observed cation influx into the cell with cation influx into the cell observed when the test substance is not contacted with the cell, a salty taste modulating substance such as salt alternative compound, or salt perception enhancing or inhibiting compound is screened.02-02-2012
20120028262GENES AND POLYPEPTIDES RELATING TO HUMAN PANCREATIC CANCERS - The present application provides novel human genes C1958V1 or C1958V2 whose expression is markedly elevated in pancreatic cancers compared to corresponding non-cancerous tissues. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of pancreatic cancer, and as target molecules for developing drugs against the disease.02-02-2012
20130260386NUCLEIC ACID CONSTRUCT SYSTEMS CAPABLE OF DIAGNOSING OR TREATING A CELL STATE - Nucleic acid construct systems are disclosed capable of diagnosing and treating a cell state (e.g. disease state). Methods of diagnosing and treating disease states using the nucleic acid constructs described herein are also disclosed. In addition, methods of screening for agents capable of reversing a disease phenotype using the nucleic acid constructs of the present invention are disclosed.10-03-2013
20130252251METHOD FOR THE DIAGNOSIS AND/OR PROGNOSIS OF INFLAMMATORY STATES - A method for the diagnosis and/or prognosis of inflammatory states, and the use of at least one soluble receptor-binding (RBD), for the identification and quantication of the expression of membrane receptors present on the surface of target granulocytes, said identification and quantification taking place at a given time or during a given time interval, and allowing the diagnosis and/or prognosis of inflammatory states in a mammal.09-26-2013
20120301892IN VITRO TEST SYSTEM TO EVALUATE XENOBIOTICS AS IMMUNE-MODULATORS OF DRUG TRANSPORT AND METABOLISM IN HUMAN HEPATOCYTES - A method of evaluating the effect of a xenobiotic on biomarkers, such as drug transporters and drug-metabolizing enzymes in hepatocytes is provided. The method comprises the formation of a xenobiotic-stimulated biological sample, such as whole blood, which contains a plurality of cytokines. A portion of xenobiotic-stimulated biological sample is cultured with hepatocytes. The hepatocytes are then analyzed to evaluate the activity of drug transporters and/or drug-metabolizing enzymes, or other biomarkers to determine the effect of the xenobiotic on drug metabolism in the hepatocytes.11-29-2012
20130210022METHOD OF IDENTIFYING AN AGENT FOR INHIBITING ODOR OF PYRAZINE DERIVATIVES - A method to identify an agent for reducing an odor of a pyrazine derivative, comprising: 08-15-2013
20110165580Response Element Regions - Response element regions, DNA constructs comprising response element regions, host cells comprising response element regions, and methods of using response element regions are provided.07-07-2011
20130029346VECTOR AND SCREENING ASSAY FOR CD44 EXPRESSING CARCINOMAS - The present invention relates, in part, to the discovery of cis-regulatory regions for the expression of CD44 in normal cells and/or and over-expression in cancer cells or cancer stem cells. To this end, the present invention provides isolated DNA, vectors, kits, and methods that may be used for the evaluation and/or screening one or more therapeutic agents for the treatment of a CD44 expressing carcinoma.01-31-2013

Patent applications in class Drug or compound screening involving gene expression